What Happened?
Cambridge, MA-based Editas Medicine has Appointed Vic Myer as Chief Technology Officer
About the Company
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine `Editors`, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we`ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
About the Person
Prior to joining Editas, Editas Myer served as executive director and Cambridge site head for the Developmental and Molecular Pathways (DMP) department at the Novartis Institutes for Biomedical Research Incorporated (NIBR). While at Novartis, he led a global team of more than 200 scientists engaged in both drug discovery and technology platform roles. Dr. Myer joined Novartis in 2004 as a research investigator and advanced over the course of this tenure there, including leading the high throughput biology team and overseeing the target discovery technologies platform. Previous to Novartis, Dr. Myer was a founding scientist and group leader at Akceli, Inc., a venture-backed systems-biology company focusing on commercialization of a high-throughput cell-based micro-array technology. Dr. Myer also served as senior scientist for Millennium Pharmaceuticals and held various roles at Corning, Inc. Dr. Myer received his B.S. in biology (biochemistry) from Cornell University and his Ph.D. in molecular biophysics and biochemistry from Yale University. He was a postdoctoral research associate at the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology.
Info Source
News
Short Profile